CAS 635318-55-7
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
3 produits concernés.
Pomaglumetad methionil anhydrous
CAS :LY2140023, potential schizophrenia treatment, is an oral prodrug of LY404039, a selective mGlu2/3 agonist.Formule :C12H18N2O7S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :366.41LY2140023
CAS :<p>LY2140023 is a novel drug that acts as an agonist of the metabotropic glutamate receptor mGlu2. It has been shown to be efficacious in animal models for the treatment of symptoms caused by disorders such as Parkinson’s disease, schizophrenia, and depression. LY2140023 is an oral prodrug that is metabolized into its active form in the liver. The drug may have potential for use in combination with other drugs to treat conditions such as Alzheimer's disease or stroke. LY2140023 has also been shown to increase locomotor activity and improve cognition in mice with a brain lesion. The long-term efficacy of the drug has not yet been established, but it has potential as a pharmacological agent for treating symptoms caused by disorders such as Parkinson’s disease, schizophrenia, and depression.</p>Formule :C12H18N2O7S2Degré de pureté :Min. 95%Masse moléculaire :366.41 g/mol
